[1] |
COHEN P A, JHINGRAN A, OAKNIN A, et al. Cervical cancer[J]. Lancet, 2019, 393(10167):169-182.
DOI
PMID
|
[2] |
XIA C, DONG X, LI H, et al. Cancer statistics in China and United States,2022:profiles,trends,and determinants[J]. Chin Med J (Engl), 2022, 135(5):584-590.
|
[3] |
陈号, 夏昌发, 由婷婷, 等. 中国女性宫颈癌负担快速上升的原因及其应对措施[J]. 中华流行病学杂志, 2022, 43(5):761-765.
|
[4] |
World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem[EB/OL]. (2020-11-17) [2023-01-07]. https://www.who.int/zh/news/item/17-11-2020-a-cervical-cancer-free-future-first-ever-global-commitment-to-eliminate-a-cancer.
|
[5] |
DE GEUS V, EWING-GRAHAM P C, DE KONING W, et al. Identifying molecular changes in early cervical cancer samples of patients that developed metastasis[J]. Front Oncol, 2022, 11:715077.
|
[6] |
HASHEMI M, MOOSAVI M S, ABED H M, et al. Long non-coding RNA (lncRNA)H19 in human cancer:from proliferation and metastasis to therapy[J]. Pharmacol Res, 2022, 184:106418.
|
[7] |
聂明月, 辛乐, 叶红. 长链非编码RNA MALAT1在宫颈癌中作用的研究进展[J]. 中华实用诊断与治疗杂志, 2022, 36(3):321-324.
|
[8] |
YU L, LI H, LI Z, et al. Long non-coding RNA HAND2-AS1 inhibits growth and migration of gastric cancer cells through regulating the miR-590-3p/KCNT2 axis[J]. Onco Targets Ther, 2020, 13:3187-3196.
|
[9] |
WEI P, YANG J, ZHANG D, et al. LncRNA HAND2-AS1 regulates prostate cancer cell growth through targeting the miR-106a-5p/RBM24 axis[J]. Onco Targets Ther, 2020, 13:4523-4531.
|
[10] |
DONG G, WANG X, JIA Y, et al. HAND2-AS1 works as a ceRNA of miR-3118 to suppress proliferation and migration in breast cancer by upregulating PHLPP2[J]. Biomed Res Int, 2020, 2020:8124570.
|
[11] |
PPOALIS M L, RAMIREZ S I, LEACH K M, et al. Improving cervical cancer screening rates:a scoping review of resources and interventions[J]. Cancer Causes Control, 2022, 33(11):1325-1333.
|
[12] |
LI T, LAI Y, YUAN J. The diagnostic accuracy of TCT + HPV-DNA for cervical cancer:systematic review and meta-analysis[J]. Ann Transl Med, 2022, 10(14):761.
|
[13] |
LI H, LI L, SUN J, et al. Value of TCT combined with serum CA153 and CA50 in early diagnosis of cervical cancer and precancerous lesions[J]. Pak J Med Sci, 2022, 38(6):1471-1476.
DOI
PMID
|
[14] |
ARBYN M, SIMON M, DE SANJOSÉ, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening:a systematic review and meta-analysis[J]. Lancet Oncol, 2022, 23(7):950-960.
|
[15] |
CAI Y, HUANG Y, ZHANG J, et al. LncRNA CBR3-AS1 predicts a poor prognosis and promotes cervical cancer progression through the miR-3163/LASP1 pathway[J]. Neoplasma, 2022, 69(6):1406-1417.
DOI
PMID
|
[16] |
LIU M Y, LI N. The diagnostic value of lncRNA HOTAIR for cervical carcinoma in vaginal discharge and serum[J]. Medicine(Baltimore), 2023, 102(26):e34042.
|
[17] |
CAO X, YAO J, JIA M, et al. Serum CCAT2 as a biomarker for adjuvant diagnosis and prognostic prediction of cervical cancer[J]. J Ovarian Res, 2022, 15(1):20.
DOI
PMID
|
[18] |
GAO Y, ZOU T, LIANG W, et al. Long non-coding RNA HAND2-AS1 delays cervical cancer progression via its regulation on the microRNA-21-5p/TIMP3/VEGFA axis[J]. Cancer Gene Ther, 2021, 28(6):619-633.
DOI
PMID
|
[19] |
HU J, WANG M, YANG Y, et al. LncRNA DLEU2 silencing impedes the migration,invasion and EMT in gastric cancer cell by suppressing PI3K/AKT signaling pathway[J]. Immunopharmacol Immunotoxicol, 2022, 44(5):719-731.
|
[20] |
SHI W J, LIU H, GE Y F, et al. LINC00673 exerts oncogenic function in cervical cancer by negatively regulating miR-126-5p expression and activates PTEN/PI3K/AKT signaling pathway[J]. Cytokine, 2020, 136:155286.
|
[21] |
李沫, 宓淑芳, 王孝信. lncRNA-CCAT1通过调控PI3K/Akt/mTOR信号通路对宫颈癌HeLa细胞自噬的影响[J]. 中国免疫学杂志, 2021, 37(15):1855-1859.
|
[22] |
GAO T, DAI X, JIANG Y, et al. LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of non-small cell lung cancer cells by inactivating PI3K/Akt pathway[J]. Biosci Rep, 2020, 40(11):BSR20201870.
|
[23] |
LI L, LI L, HU L, et al. Long non-coding RNA HAND2-AS1/miR-106a/PTEN axis re-sensitizes cisplatin-resistant ovarian cells to cisplatin treatment[J]. Mol Med Rep, 2021, 24(5):762.
|